FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Catalog category
Tirzepatide, Semaglutide, Retatrutide, Cagrilintide and related GLP-1 / GIP / GCG receptor agonists for metabolic and weight-management research.
7 actives in this category · per-lot documented · pricing on request.
What buyers source Metabolic & GLP-1 for, which buyer types order it, and the documentation that ships with each lot.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Supplied as a documented active in acetate counter-ion form by default; the buyer verifies current scheduling and compounding eligibility for the destination market.
Metabolic & GLP-1 actives
GIP / GLP-1 dual receptor agonist
GIP / GLP-1 / glucagon tri-agonist
GLP-1 receptor agonist
Long-acting amylin analog
GLP-1 receptor agonist (long-acting)
GLP-1 / glucagon dual receptor agonist (IBI362 / LY3305677)
GLP-1 / glucagon dual receptor agonist (BI 456906)
Sold as a pharmaceutical-grade active for research and for compounding-pharmacy formulation in jurisdictions where local regulations permit. Not a finished dosage form and not labeled for direct human administration as shipped. The GLP-1 class is on active regulatory watchlists in several major markets, buyers are responsible for verifying current scheduling and compounding eligibility for the destination at the time of dispense.
First response under 12 hours · Catalog · Sample COA · MOQ · Lead time. Our regulatory and sales teams review every inquiry before pricing — license verification on every request.
